Table 1.
Characteristics of Study Subjects
| Characteristic | Patients With CMV Pneumonia (n = 132) |
Asymptomatic CMV Shedders (n = 21) |
Patients With IPS (n = 18) |
Patients With Non-CMV Pneumonia (n = 100) |
|---|---|---|---|---|
| Male sex | 70 (53.0) | 13 (61.9) | 9 (44.4) | 59 (59.0) |
| Age, y, median (IQR) | 44.0 (32.5–54.2) | 35.4 (33.8–45.1) | 44.1 (36.1–48.1) | 50.9 (41.5–56.7) |
| Underlying disease | ||||
| AML | 31 (23.5) | 8 (38.1) | 3 (16.7) | 22 (22.0) |
| ALL | 15 (11.4) | 1 (4.8) | 1 (5.6) | 5 (5.0) |
| CML | 32 (24.2) | 10 (47.6) | 7 (38.9) | 13 (13.0) |
| MDS | 19 (14.4) | 0 | 5 (27.8) | 20 (20.0) |
| NHL | 14 (10.6) | 2 (9.5) | 0 | 9 (9.0) |
| MM | 7 (5.3) | 0 | 1 (5.6) | 7 (7.0) |
| Other | 14 (10.6) | 0 | 1 (5.6) | 24 (24.0) |
| HLA donor status | ||||
| Autologous | 9 (6.8) | 0 | 0 | 14 (14.0) |
| Matched related | 47 (35.6) | 11 (52.4) | 6 (33.3) | 30 (30.0) |
| Mismatched related | 12 (9.1) | 2 (9.5) | 3 (16.7) | 3 (3.0) |
| Unrelated | 64 (48.5) | 8 (38.1) | 9 (50.0) | 53 (53.0) |
| Graft source | ||||
| BM | 69 (52.3) | 21 (100.0) | 15 (83.3) | 35 (35.0) |
| PBSCs | 58 (43.9) | 0 | 3 (16.7) | 60 (60.0) |
| BM and PBSCs | 1 (0.8) | 0 | 0 | 1 (1.0) |
| Cord blood | 4 (3.0) | 0 | 0 | 4 (4.0) |
| Conditioning regimen | ||||
| Myeloablative | ||||
| With TBI (>1000 cGy) | 71 (53.8) | 18 (85.7) | 13 (72.2) | 31 (31.0) |
| Without TBI | 37 (28.0) | 3 (14.3) | 5 (27.8) | 47 (47.0) |
| Reduced intensity (with and without low-dose TBI) | 24 (18.2) | 0 | 0 | 22 (22.0) |
| Acute GVHDa | ||||
| Grade 2–4 | 107 (87.0) | 14 (66.7) | 13 (72.2) | 61 (70.9) |
| Grade 3–4 | 41 (33.3) | 8 (38.1) | 12 (66.7) | 32 (37.2) |
| CMV serostatus | ||||
| D+R+ | 69 (52.3) | 6 (28.6) | 6 (33.3) | 56 (56.0) |
| D−R+ | 51 (38.6) | 11 (52.4) | 7 (38.9) | 40 (40.0) |
| D+R− | 5 (3.8) | 4 (19.0) | 5 (27.8) | 4 (4.0) |
| D−R− | 7 (5.3) | 0 | 0 | 0 |
Data are no. (%) of patients, unless otherwise indicated. Percentages may not equal 100%, owing to rounding.
Abbreviations: ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; CML, chronic myeloid leukemia; CMV, cytomegalovirus; D, donor; GVHD, graft-versus-host disease; IPS, idiopathic pneumonia syndrome; IQR, interquartile range; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; PBSC, peripheral blood stem cell; R, recipient; TBI, total body irradiation; −, negative; +, positive.
aData are limited to allogeneic transplant recipients; no GVHD data were available for 7 patients with CMV pneumonia and 13 with non-CMV pneumonia.